Shanghai, China, 28 November 2022 – MicroPort Scientific Corporation (MicroPort ® ), a global leading medical device company, announced today that the last patient enrollment for the TARGET IV-NA clinical trial has been completed at the Quebec Heart Lung Institute, Quebec, Canada.
Infective Endocarditis With Stroke Post-TAVR: Dismal Prognosis medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.